



# Office for Barbados and the Eastern Caribbean Countries


### WEBINAR

Variant of Concern (VOC) **Delta** to **Omicron**, Transmissibility, Severity, Impact of Social Mobility - What will drive future trends and Optimizing our response

### Wednesday, 15 December 2021, 9:30am - 11:00am

Overview of the webinar objectives and country preparedness plan for the surge of cases over the holiday

Dr. Yitades Gebre PAHO/WHO Representative for Barbados and the Eastern Caribbean Countries



# **Objectives**

To discuss factors contributing to the increase cases during and after the holiday season and Prevention steps to reduce the spread

To provide information on the factors driving transmission of the new VOC Omicron and Delta SARS-CoV-2

To discuss the impact of social mobility and social mixing and importance of public health and social measures

To strengthen the health systems and services for clinical management for patients with Severe Covid-19 Cases

To advise all countries to reassess and revise national plans based the current situation for the new year



# Agenda

9:30

Welcome introduction-Moderator, Ms. Nicola Barriteau

#### 9:40 - 9:55

Overview of the webinar

preparedness plan for the surge of case over the

objectives and country

Dr. Yitades Gebre

9:35 - 9:40

holiday

What do we know-the situation update and epidemiology on Covid-19 and VOC Omicron **Dr. Prabhjot Singh** 

Q & A

9:55 - 10:10

#### 10:10 - 10:25

Strengthening the health system and services in response to covid-19 severe cases and hospitalization

#### Dr. Maria Cecilia Acuna

The impact of social mobility and social mixing and importance of public health and social measures-

#### Ms. Martine Chase

10:25 - 10:40

Conclusion Moderator and Dr. Yitades Gebre

10:55

10:40 - 10:55

Q&A



### What will continue to drive future trends?

#### Frequency and magnitude of subsequent waves will depend on multiple factors:

- Population level immunity from natural infection and/or vaccination, including
  - Extent of infection
  - Extent of vaccination
    - · Vaccine characteristics and efficacy
    - Strategy and priority groups (e.g., at risk groups, by age group)
    - Extent of vaccination coverage/resistance
  - Duration of protection against severe disease/death and infection (vaccine, natural immunity)
- Severity of disease, access to early clinical care and availability of therapeutics
- VOCs emerging and circulating, and transmissibility of VOCs, properties of immune escape
- Use of Public Health and Social Measures, including:
  - Type of measures identify most effective measures at lowest cost (pandemic fatigue, political/economical cost)
  - Timeliness of implementation
  - Adherence to measures






### **Factors driving transmission**

- The virus continues to evolve resulting in more transmissible variants
- Highly susceptible population: Driven by unequal vaccine distribution & access to live saving tools, a large proportion of the world population remains susceptible to infection & at increased risk of severe disease and death
- Increased social mobility and social mixing provides increases exposure to the virus, combined with Inappropriate, inconsistent use of proven Public Health and Social Measures
- Misinformation, disinformation, conflicting messaging, politicization










Citation style for this article: Hodgson David, Flasche Stefan, Jit Mark, Kucharski Adam J, CMMID COVID-19 Working Group. The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant. Euro Surveill. 2021;26(20):pii=2100428. https://doi.org/10.2807/1560-7917.ES.2021.26.20.2100428 Received: 29 Apr 2021; Accepted: 20 May 2021

### What do we know – current situation and epidemiology of Covid-19 and Variant of Concern Omicron

Dr. Prabhjot Singh PAHO Advisor, Health Surveillance & Disease Control and Prevention



### **Table of contents**

2

**Current COVID-19 Situation Globally** 

4

3

#### Situation & Projections for ECC & Barbados

**OMICRON** Variant






### **Global Situation**

(as of 3 December 10H CET)

- Previous 24 hours:
  - 653,682 new confirmed cases.
  - 7,804 new deaths.
- Cumulative:
  - 263,563,622 confirmed cases.
  - 5,232,562 deaths.



Countries with the highest number of new cases in previous 24 hours

Country		New Cases	Total Cases	New Deaths	Total Deaths
United States of America	~~~	131,187	48,413,265	1,831	778,336
Germany	$\sim$	74,352	6,051,560	390	102,568
United Kingdom	1 Jun	53,067	10,329,078	141	145,281
France	$\sim$	48,129	7,538,806	97	116,847
Russian Federation	$\sim$	32,930	9,736,037	1,217	278,857
Poland	$\checkmark$	26,961	3,623,452	470	85,126
Netherlands	m	23,142	2,684,734	65	19,524
Turkey	$\sim$	21,747	8,839,891	192	77,230
Czechia	$\sim$	18,582	2,211,972	50	33,450
Italy	$\sim$	16,810	5,060,430	72	134,003

Trend line shown for the past 12 months

data smoothed with 7-day moving average

# COVID-19 Incidence – cases per 1000 people

Country /			Ma	у			Ju	ın			Jı	ul				Aug	5			Se	pt			0	ct			N	ov			ĺ	Dee	2		Country /
Territory	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	Territory
Antigua and	0.1	0.1	0.1	0	0	0	0	0	0	0	0.1	0.1	0.2	0.4	0.6	1 2	1 0	17	12	A A	12	27	26	15	1.2	0.5	0.2	0.2	0.1	0.1	0					Antigua and
Barbuda	0.1	0.1	0.1	0	U	U	U	0	0	0	0.1	0.1	0.2	0.4	0.0	1.5	1.0	1.7	4.5	4.4	4.2	5.7	2.0	1.5	1.2	0.5	0.5	0.5	0.1	0.1	U					Barbuda
Barbados	0.2	0.1	0.1	0	0	0	0	0.1	0	0.2	0.3	0.3	0.2	0.2	0.2	0.3	0.8	1.1	1.7	1.9	3.6	4.2	5.8	5.2	8.2	8.4	7.2	7	5.3	3.9	3.2	2.5				Barbados
Dominica	0	0	0.1	0.1	0	0	0	0	0	0	0.1	0	0.1	2.1	7.7	5.5	4.1	2.7	6.9	5.5	5.3	5.3	4.4	0.9	4.9	3.8	2.5	0	8.9	1.9	4.3	2				Dominica
Grenada	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0.3	0.7	7.8	9.8	13	6.7	3.3	2.4	1	0.6	0.2	0.2	0	0.1	0.1	0.2	0.1				Grenada
St. Kitts & Nevis	0	0	0.1	0.3	0.2	2	2.7	1.6	1.1	0.7	0.4	0.3	0.5	0.4	0.8	3.1	4.3	3.3	4.4	3.7	3.6	2.3	6.8	2.6	1.3	0.8	0.9	0.6	0.3	0.2	0.1	0.1				St. Kitts & Nevis
St. Lucia	0.5	0.9	0.7	0.6	0.2	0.2	0.2	0.3	0.2	0.4	0.3	0.2	0.5	0.8	2.4	4	4.4	5	3.7	3	2.9	2.5	1.5	1.1	1.1	0.7	0.6	0.5	0.4	0.4	0.3	0.3				St. Lucia
St. Vincent &	0.2	0.2	0.2	0.4	0.2	0.2	0.4	0.2	0.1	0	0.2	0.1	0.2	0	0.1	0	0.1	0.4		2 5	4.6	2	2.0	2.0	2	4.2	0.0	1 2	0.0	0.0		0.0				St. Vincent &
Grenadines	0.3	0.2	0.3	0.4	0.3	0.3	0.4	0.2	0.1	0	0.2	0.1	0.2	U	0.1	0	0.1	0.4	1	2.5	4.6	3	3.8	2.9	2	1.2	0.9	1.3	0.6	0.8	0.9	0.9				Grenadines
Anguilla	0.3	0.7	0	0	0	0	0	0	0.1	0	0.1	0	0.1	0	0.9	1.9	1.9	4.1	1.1	0.9	2.2	4	7.9	8.2	8.3	10	6.3	6.5	8.7	4.4	5.3	7.2				Anguilla
Montserrat	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0.2	0.2	0.4	0.2	0.4	0.2	0.2	0	0.2	1.4	0	0	0	0	0	0.6	0	0	0				Montserrat
Virgin Islands (UK)	0.8	1	0	1.3	0	0.2	0	0.1	5.2			12	3.7	1.1	0.7	0.5	0	2.4	0.1	0	1.1	1.4	0.2	0	0	0	0	0	0.7	0.3	1.4	0.9				Virgin Islands (UK)
French Guiana	2.2	2.7	3.1	2.2	2.2	1.9	2.2	2.1	1.3	1.3	1.2	1.8	1.6	1.8	2.4	2.9	3	3.1	2.7	3.4	3.5	5	2.7	1.9	1.6	1.3	1.3	0.7	0.6	0.6	0.5	0.7				French Guiana
Martinique	0.9	0.5	0.3	0.5	0.2	0.2	0.2	0.2	0.3	1.1	5.8	6	14	9.9	7.8	6.2	3.3	2.7	2	1.6	1.1	0.9	1	0.9	1	0.9	0.8	0.5	1.8	1.5	1.7	1.6				Martinique
Guadeloupe	2	1.6	1.1	0.9	0.6	0.4	0.3	0.3	0.4	0.3	0.4	0.8	2.7	3.8	7.5	6.7		10	4.9	2.4	1.6	1.1	0.7	0.6	0.5	0.5	0.5	0.5	0.6	0	0.3	0.4				Guadeloupe
St. Barthelemy	0.6	1.6	0.6	0.7	0.6	0.3	0.8	0.3	0.3	0.6	0.5	0.8		6.5	2.6	2.1	3.9	1.5	0.6	1.1	1	1.5	0.9	0.1	0	0.1	0.1	0	0.5	0.6	0.2	0.9				St. Barthelemy

Transmission Intensity Low 0 1 3 4 High


### **Projections: Jan – Feb (60-day period)**

		By End Feb										
Country	Rt		Med.	Hospitali	ICU							
		Sick	Consults	zations	Adm.	Deaths						
Anguilla	1.38	1016	508	203	85	6						
Antigua and Barbuda	2.03	2444	1222	489	205	8						
Barbados	0.84	1870	935	374	157	13						
Saint Kitts and Nevis	0.97	120	60	24	10	1						
Dominica	0.27	381	190	76	32	3						
Grenada	0.53	80	40	16	7	0						
Martinique	0.91	2147	1073	429	180	14						
Saint Lucia	0.86	243	122	49	20	2						
French Guiana	1.11	1547	774	309	130	10						
St. Vincent & the												
Grenadines	1.04	541	271	108	45	3						

Cautious use of estimates – based largely on reported data and surveillance assumptions – wide confidence intervals for some




## **COVID-19 Deaths**




Age (bin) 🖈

## **COVID-19 Deaths**




# Vaccine Coverage in ECC and Barbados




Percentage Coverage of Total Population \*

# Vaccine Coverage in ECC and Barbados



## **COVID-19 in South Africa** Omicron after two intense waves of Beta and Delta variants





# **COVID-19 in South Africa – Gauteng State**

- Hospitalizations are increasing but still a fraction of that during Delta wave
- Not all hospitalizations can be attributed to Omicron
- Minimal increase in deaths
- Lag time between cases
  hospitalizations –
  deaths still not
  remaining

Source: https://www.nicd.ac.za/diseasesa-z-index/disease-index-covid-19/surveillance-reports/daily-hospitalsurveillance-datcov-report/

#### Hospital admissions of COVID-19 cases, by health sector, by epidemiological week





# **Countries with detected confirmed Omicron cases by WHO Region**


#### Signals as of 5 Dec 2021, 4pm CET

	Unverified report	Verified report	Number of countries reporting Omicron
AFRO			8
Botswana		x	
Ghana		x	
Nigeria		x	
Réunion		х	
Senegal	X		
South Africa		x	
Zambia		x	
Zimbabwe	X		
EMRO			3
Saudi Arabia		x	
Tunisia		x	
United Arab Emirates		x	
PAHO			5
Brazil		x	
Canada		x	
Chile		x	
Mexico		x	
SEARO			2
India		x	
Sri Lanka	X		
WPRO			6
Australia		x	
China		X	
Japan		x	
Malaysia		x	
Republic of Korea		x	
Singapore	X		

	Unverified report	Verified report	Number of countries reporting Omicron
EURO			2
Austria		x	
Belgium		x	
Czechia		X	
Denmark		X	
Finland		X	
France		X	
Germany		X	
Greece		x	
Iceland		x	
Ireland		x	
Israel		x	
Italy		x	
Luxembourg		X	
Netherlands		x	
Norway		x	
Portugal		x	
Romania		x	
Spain		x	
Sweden		x	
Switzerland		x	
United Kingdom		x	
TOTAL			4

- Signals of suspected cases are monitored and will only be reported as they are confirmed
- Reports of suspected cases are not included in the table






#### Since last update: Bermuda + Cuba + Argentina + Trinidad and Tobago






# **Delta is Still the Most Prevalent Variant**

**Emergencies Programme** 



#### Timecourse of variant distribution in all submitted sequences 2021-12-03




the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Prevalence data based on sequences reported to GISAID, excluding low coverage sequences. See also Annex 2 for reported VOC detections by country/territory/area

# Recommendations

- Risk based assessment
  - Objective:
    - Prevent Deaths
    - Prevent Cases
    - Prevent Introduction
  - Testing Options: PCR and Rapid Antigen Tests
- Preparing: Forecasting needs and procurement
- Public Health and Social Measures
  - Masks, Hand Sanitizing, Social Distancing and VENTILATION






### Key Messages / What we Know

- Omicron is probably more transmissible
- Current detection methods are adequate for its diagnosis (PCR and antigen tests)
- Effect on severity of disease and vaccine efficacy is still under study
- Measures to be taken:
  - Masks, hand sanitizing, social distancing and ventilation
  - Risk based assessment of entry protocols, quarantine and testing strategy
  - Encourage Vaccination



Strengthening the health system and services in response to Covid-19 severe cases and hospitalization

Dr. Maria Cecilia Acuna PAHO Advisor, Health Systems and Services



### **Current knowledge about Omicron**

Transmissibility: Omicron is more transmissible. It is not yet clear whether it causes more or less severe disease compared to other variants, or impacts the effectiveness of current COVID-19 vaccines	Re in fect ion : Preliminary evidence suggests there may be an increased risk of reinfection with Omicron, however information is limited*	Detection: Diagnostic tests, including PCR and antigen detection tests, continue to detect infection with Omicron	Clinical management: Corticosteroids and IL-6 receptor blockers do not target the spike protein and are still effective for managing patients with severe COVID-19
--	--	---	--

While characteristics of Omicron are being studied, evidence shows that COVID-19 vaccines are still effective to protect against severe disease due to current circulating SARS-CoV-2 variants, including Delta

\*https://www.who.int/news/item/28-11-2021-update-on-omicron



### The health system response

A higher transmissibility increases the probability of a rapid rise in hospitalizations

Interventions at community level under the leadership of the PHC teams are key to ensure adequate care for mild and moderate cases and to keep hospitals available for severe and critical cases

The best way to reduce hospitalizations is to vaccinate the at-risk and vulnerable population

There are lessons to be learned from the past 22 months




# Americas report surge in drug-resistant infections due to misuse of antimicrobials during pandemic

17 Nov 2021



- Data shows that more than 90% of hospitalized COVID patients in the Americas were given an antimicrobial, while only 7% required these drugs to treat a secondary infection.
- Drugs such as Ivermectin, Azithromycin and Chloroquine were also widely used, despite strong evidence that they have no benefit against COVID-19.
- Funds saved by avoiding the purchase of unnecessary medicines can be invested in medicines and other health technologies with proven efficacy

### Population



Infographic co-produced by the BMJ and MAGIC; designer Will Stahl-Timmins (see BMJ Rapid Recommendations).



# Pharmaceutical management of severe/critical patients

New strong recommendation for use of IL6-receptor blockers for patients with severe/critical COVID-19 (tocilizumab, sarilumab)

- Immunomodulator function
- Reduction in mortality and need for mechanical ventilation

#### Therapeutics and COVID-19

Living guideline 7 December 2021

# Three pillars of pharmaceutical treatment for patients with severe/critical COVID-19

#### **OXYGEN + CORTICOSTEROIDS + IL6-Receptor blockers**

#### NOT recommended regardless of COVID-19 disease

- a conditional recommendation against remdesivir;
- a strong recommendation against hydroxychloroquine;
- a strong recommendation against lopinavir/ritonavir;
- a recommendation against ivermectin, except in the context of a clinical trial.







PAHO (S) Pan American Health Organization

Available at: <u>https://iris.paho.org/handle/10665.2/53895</u>

The use of tocilizumab is suggested for the critical patients who received corticoesteroids.

> DRUG THERAPY FOR CRITICAL PATIENTS WITH COVID-19

lopinavir/ritonavir, chioroquine or hydroxychloroquine, with or without azithromycin, colchicine and convalescent plasma, are not recommended for the management of the patients with COVID-19, nor for the conduct of clinical trials.

Remdesivir,

Low dose corticosteroids

are recommended in critical patients requiring

supplemental oxygen or

ventilation.

Antibiotic therapy should be initiated within an hour of assessing the patient. Antibiotics should be scaled back on the basis of microbiology results and clinical judgment.

......

Administer antipyretics. Do not use NSAIDs.

Use of the following drugs is not recommended outside of the context of clinical trials:

Pharmacological

prophylaxis with low

molecular weight heparin

(LMWH) in accordance with local and international standards.

Antiparasitics
 Antivirals
 N-acetyl cysteine
 Immunomodulators except
 tocilizumab

# Core elements of successful containment strategies across the health system


- Organize isolation centers and treatment facilities for mild and moderate cases at community level
- Promote self-isolation of mildly symptomatic patients, set up health hotlines and remote health consultation
- Establish a national plan to recruit, hire, train and retain Health Care Workers
- Increase the availability of personal protective equipment for the healthcare workers
- Increase inpatient capacity. Reduce the number of non-COVID-19 or mild COVID-19 patients in medical centers and hospitals
- Ensure availability of essential medical supplies and equipment for the treatment of severe and critical patients. Follow the Guidelines!!
- Provide training in oxygen management: not only for the clinical teams



#### **The WHO Global Clinical Platform for Covid-19**


Countries contributing data to the WHO Platform (June, 2021)

#### **Global COVID-19 Clinical Data Platform: Data Contributors**



https://www.who.int/teams/health-care-readiness-clinical-unit/covid-19/data-platform





## Free COVID-19 online courses on OpenWHO and PAHO VCPH

#### Clinical management of patients with COVID-19:

- General considerations
- Initial approach to the acutely ill patient
- Investigations and care for mild, moderate and severe disease
- Rehabilitation of patients with COVID-19
- Online training (who.int)

#### COVID-19 Clinical management: living guidance (who.int)

### Hospital Readiness checklist for for COVID-19

Interim document - Version 5. February 10, 2020

	Evaluation date:									
	Name of the hospital:									
	City:	Country:								
	Administrative status: state private unive	rsity other								
	Beds:	Annual discharges:								
	Annual occupied bed days:									
	Beds Intensive Care Unit (ICU):	Microbiology laboratory: Y O N O								
Description	ICU beds for adults:	Number of isolations / year:								
of hospital	ICU beds for pediatrics:	Number of antibiograms / year								
or noopna.	ICU beds for neonatology:									
	Names and positions of the people interviewed:									
	Name of evaluators:									

			Readiness checklist			
Response	Objective		Response-readiness activities	Ve	erificatio	on
functions	Objective		Response-readiness activities	Meets	Does not meet	In Process
Leadership	Ensure comprehensive management of the hospital response to the emergency	1 2 3 4 5 6 7	Activate the emergency response mechanism: Hospital Committee for Emergencies and Disasters and/or Hospital Incident Management System. Designate a response operations manager. Establish a secure and well-equipped physical area that is protected and easily accessible, with immediate operational capacity to coordinate the response (Emergency Operations Center), paying attention to internal and external communications. Assign roles and responsibilities for the different response functions, with enough trained staff available to ensure operational continuity; include up-to-date directory of telephone numbers and email addresses. Designate official spokespersons. Use occupational health mechanisms that ensure the well-being and safety of personnel during the response, including monitoring of exposed personnel. Distribute information to all staff about the emergency and the roles and responsibilities of personnel and the hospital, as well as current and future actions.	00000000		

Response			Description of the second state	Verification					
functions	Objective		Response-readiness activities	Meets	Does not meet	In Process			
Coordination	Ensure proper functioning of coordination mechanisms	8 9	Identify and establish coordination mechanisms with health and disaster management authorities. Activate mechanisms for coordination, communication, and collaboration with the integrated health services network at the level local, considering patient care, the necessary drugs, supplies and equipment, and patient transfer.	0	0	0			
Information	Compile, compare, and analyze information on developments in the emergency, response management, and other contextual data on existing risks and needs	10	Make procedures and personnel available to collect, confirm, and validate data and information related to the emergency. Provide a standardized form for reporting on emergency activities, hospitalizations (including critical care), incidence of suspected and confirmed cases, clinical situation, and deaths.	<ul><li></li><li></li><li></li></ul>	0 0	0			
		12	Establish a physical space to triage patients with acute respiratory symptoms. Locate a space with optimal conditions for the prevention and control of infections.	$\circ$	$\circ$	$\circ$			
		13	Identify areas that can be used to increase patient care capacity (expanded capacity), considering the necessary personnel, equipment, and supplies.	$\circ$	$\circ$	$\circ$			
	Facilitate emergency	14	Identify nonessential services that could be suspended, if necessary, in order to increase hospital capacities (human and material resources, equipment, and physical space).	$\bigcirc$	$\bigcirc$	$\circ$			
Logistics and operations	response, supported by the logistical capacities of the facility	15	Have a procedure in place and someone responsible for supply chain management (medicines and supplies), considering increased demands on the supply and distribution chain, and respecting technical specifications and established protocols.	0	$\circ$	0			
		16	Have a procedure in place and someone responsible for the management of work teams, including rest areas, safe transportation, and staff well-being.	$\bigcirc$	$\bigcirc$	$\bigcirc$			
		17	Test the facility's telecommunications systems. Have a procedure in place and someone responsible for	$\circ$	$\bigcirc$	$\circ$			
		18	the management of ambulances for transportation between hospitals and for the inventory of available vehicles.	$\circ$	$\bigcirc$	$\circ$			
	Implement	1							
Administration and Finance	financial, managerial, and administrative support mechanisms needed for the	19	Activate legally available and authorized administrative and financial mechanisms for emergency management, as well as procedures for the purchase and procurement of supplies and services.	$\bigcirc$	$\circ$	0			

PAHO

Pan American Health Organization

## WHO COVID-19 Essential supplies forecasting tool

#### Implementing COVID 19 Essential Supplies Forecasting Tool

This slide provides information regarding implementation of COVID 19 essential supplies forecasting tool (ESPT) that helps to manage and organize essential medical supplies during the pandemic.

This tool will help government authorities, partners and other stakeholders estimate their potential requirements for essential supplies.

14 1-

This tool forecasts essential supplies and medical services during COVID 19 pandemic

The current version of the tool covers 5 major categories of essential supplies i.e.

> Hygiene

- > PPE (personal protective equipment)
- Drugs and medications
- Diagnostics
- Biomedical equipment's.




This tool is user triendly and its implementation will allow the user to estimate medical supplies.

Inputs that are forecasted by the tool are equipment use, cumulative case count, oxygen usage, testing criteria's, medical supplies requirements etc.

This slide is 102% editable. Adapt it to your needs and capture your audience's attention.

Estimate the gaps in personal protective equipment, diagnostic kits, consumable medical supplies, essential drugs and biomedical equipment that will be needed for supportive care and treatment of COVID-19 in the next three months

#### A more organized and comprehensive approach to preparedness



# Because no one will be safe until everyone is safe

Building resilient health systems to reach universal health Universal health Access and coverage for al Salud universal Access y coberture para todos Saúde universal Acesso e coberture para todos

Santé universelle Accèset couverture pour tous


Organización Mundial de la Salud

Inganización Anamericanz

Salue

# The impact of social mobility and social mixing and the importance of public health and social measures

Ms. Martine Chase PAHO Consultant



### Outline

- 1. Drivers of COVID-19 Transmission
- 2. Overview of Public Health & Social Measures (PHSMs)
- 3. Assessing the Intensity and Effect of PHSMs
- 4. Trends in PHSM Intensity and Transmission in select ECTs
- 5. Considerations for Adjusting PHSMs
- 6. Key Messages



# **Drivers of COVID-19 Transmission**

During community transmission, incidence is impacted by key factors including:

- 1. Population level immunity
- 2. Characteristics of dominant variants
- 3. Population mobility and social mixing (increased number of contacts and likelihood of exposure to COVID-19)

Public health and social measures that limit mobility and support personal protection remain important tools in the control of COVID-19 transmission





# **Overview of Public Health & Social**

- **1.** Aim to reduce interpersonal contact (and probability of exposure)
- 2. Range from personal protection, to restrictions on movement and physical distancing
- 3. Effectiveness is influenced by timing, stringency and compliance
- **Complement** surveillance and vaccination measures 4.

Relaxing too early can contribute to resurgence; adjustments should be phased and based on epidemiological, health system and socioeconomic data.

Mendez-Brito, Alba et al. (2021) Systematic review of empirical studies comparing the effectiveness of non-pharmaceutical interventions against COVID-19. Journal of Infection. Volume 83. Issue 3. 281 – 293 Wang, Z, Whittington, J, Yuan, H-Y, et al (2021) Evaluating the effectiveness of control measures in multiple regions during the early phase of the COVID-19 pandemic in 2020, Biosafety and Health (2021), doi: https://doi.org/10.1016/j.bsheal.2021.09.002 Wei Lyu and George L. Wehby (2020) Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US. Health Affairs 2020 39:8, 1419-1425 Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, Pinior B, Thurner S, Klimek P (2020). Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav. 2020 Dec;4(12):1303-1312. doi: 10.1038/s41562-020-01009-0. Epub 2020 Nov 16. PMID: 33199859.



# **Public Health & Social Measures (PHSMs)**

	Domain	Select PHSMs
1	Personal Protection	Masks: Use of masks/ face coverings
2	Movement	Travel: Restrictions on International Travel (Border Health)
3		Movement: limitations on domestic movement
4	Physical	Gatherings: Limitations to Mass Gatherings
5		Business: Adjustments to operations of Businesses & Institutions
6		Schools: Adjustments to educational teaching modalities




WEARING OF MASKS/ FACIAL COVERINGS	No Mask Policy		Required in some settings (e.g. public transport)	Required mask wearing in all settings
Intensity Score	0	33	67	100

World Health Organization (May 18, 2020) Overview of public health and social measures in the context of COVID-19. Interim Guidance. Available online at [Overview of Public Health and Social Measures in the context of COVID-19 (who.int)] Date accessed: September 6, 2021


World Health Organization (2020) A systematic approach to monitoring and analysing public health and social measures (PHSM) in the context of the COVID-19 pandemic: underlying methodology and application of the PHSM database and PHSM Severity Index. Copenhagen: WHO Regional Office for Europe; 2020. Licence: CC BY-NC-SA 3.0 IGO.

# **Assessing the Intensity and Effect of PHSMs**



Zweig S, Zapf A, Xu H, Li Q, Agarwal S, Labrique A, Peters D (2021) Impact of Public Health and Social Measures on the COVID-19 Pandemic in the United States and Other Countries: Descriptive Analysis JMIR Public Health Surveill 2021;7(6):e27917 URL: https://publichealth.jmir.org/2021/6/e27917

# **Assessing the Intensity and Effect of PHSMs**




#### Analysis of PHSMs in 73 countries

#### Top 6 PHSMs:

- I. Small gathering cancellation
- 2. Closure of educational institutions
- 3. Border restrictions
- 4. Increase availability of PPE
- 5. Individual movement restrictions
- 6. National Lockdown


Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, Pinior B, Thurner S, Simek P (2020). Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum 44 Behav. 2020 Dec;4(12):1303-1312. doi: 10.1038/s41562-020-01009-0. Epub 2020 Nov 16. PMID: 33199859.

## Trends in COVID-19 cases and PHSM Intensity in select ECTs (March 2020- October 31, 2021)




Preliminary analysis of the policy intensity in select ECTs based on public reported policies on masks, business closures, school closures, mass gatherings, international travel restrictions and domestic travel restrictions

#### Trends in COVID-19 cases and PHSM Intensity in select ECTs (September 2020- April 2021)



Preliminary analysis of the policy intensity in select ECTs based on public reported policies on masks, business closures, school closures, mass gatherings, international travel restrictions and domestic travel restrictions

#### **Trends in COVID-19 cases and PHSM Intensity in select ECTs** (April 2021 – October 2021)



60 - 100

Preliminary analysis of the policy intensity in select ECTs based on public reported policies on masks, business closures, school closures, mass gatherings, international travel restrictions and domestic travel restrictions



# **Considerations for Adjusting PHSMs**

Consider the readiness of the health system to respond a surge of cases before PHSM are relaxed. Specifically:

- The capacity to detect cases and return results for SARS-COV2 PCR tests within 24 hours
- The readiness of the system to conduct field investigations and provide quarantine facilities
- The ability to provide health services for an increase in cases (facility-based care and home isolation)



# **Considerations for Adjusting PHSMs**

The socio-economic cost is a major consideration when increasing the stringency of policies. What is effective at the lowest (socio-economic) cost?

With high compliance, personal protective and physical distancing measures can be effective

- 1) Mask Policies: 100% mask policy for all non-household interactions and for caregivers of the elderly or vulnerable persons (including household or family members)
- 2) Limiting Social Gatherings: Limiting social gatherings and strict physical distancing in all public settings
- **3) Incremental Relaxation:** could involve setting specific policies based on vaccination status and or recent test results
- **4) Early testing:** Reinforce messages of early testing for persons with respiratory symptoms (and known exposures)






1. PHSMs remain an important component of our response to COVID-19

- 2. Effectiveness of measures will depend on timing, stringency of policies and adherence levels
- 3. Limiting social gatherings and supporting adherence to personal protective measures can be useful strategies with comparatively low socio-economic impacts



# **Questions & Answers**



# **Advice for all countries**

#### Advice for all countries

- All countries should regularly to reassess and revise national plans based on current situation and national capacities
- Accelerate vaccine coverage in at risk populations identify those populations who are missed and target vaccination to those most vulnerable in country
- Intensify efforts to drive down/keep down transmission strengthen PHSM
- Strengthen surveillance, share data and samples, surge capacities
- Need collective approach to better assess Omicron

#### What countries should expect in the short term

- Increase incidence of infection with Delta expected where PHSMs are being relaxed, regardless of vaccination rollout: need to prepare for ongoing circulation of SARS-CoV-2 and prepare for surges
- · There will be more variants, yet the impact of Omicron is not yet clear

#### We need to optimize our response for Delta which will benefit any future variants, including Omicron





### Year of Health and Care Workers 2021

**Recognize and commemorate all health and care workers who have lost their lives during the pandemic.** 

We all have a role to play to ensure that our health and care workforces are supported, protected, motivated and equipped to deliver safe health care at all times, not only during COVID-19.





